brentuximab vedotin
View Patient InformationAn antibody-drug conjugate (ADC) directed against the tumor necrosis factor (TNF) receptor CD30 with potential antineoplastic activity. Brentuximab vedotin is generated by conjugating the chimeric anti-CD30 monoclonal antibody SGN-30 to the cytotoxic agent monomethyl auristatin E (MMAE) via a valine-citrulline peptide linker. Upon administration and internalization by CD30-positive tumor cells, brentuximab vedotin undergoes enzymatic cleavage, releasing MMAE into the cytosol; MMAE binds to tubulin and inhibits tubulin polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. Transiently activated during lymphocyte activation, CD30 (tumor necrosis factor receptor superfamily, member 8;TNFRSF8) may be constitutively expressed in hematologic malignancies including Hodgkin lymphoma and some T-cell non-Hodgkin lymphomas. The linkage system in brentuximab vedotin is highly stable in plasma, resulting in cytotoxic specificity for CD30-positive cells.
Synonym: | anti-CD30 ADC SGN-35 anti-CD30 antibody-drug conjugate SGN-35 anti-CD30 monoclonal antibody-MMAE SGN-35 anti-CD30 monoclonal antibody-monomethylauristatin E SGN-35 antibody-drug conjugate SGN-35 |
---|---|
US brand name: | Adcetris |
Abbreviation: | cAC10-vcMMAE |
Code name: | ADC SGN-35 SGN-35 |